Weinblatt ME, et al. - The 24-week equivalent efficacy and comparable safety results of SB5 and reference adalimumab (ADA) from the phase 3 randomized study in patients with moderate to severe rheumatoid arthritis (RA) have been reported previously. In this trial, experts assessed the cases with moderate to severe rheumatoid arthritis (RA) that switched from adalimumab (ADA) to SB5 or continued on SB5 or ADA up to 52 weeks. Findings revealed that in patients with RA, SB5 was well tolerated over 1 year with comparable efficacy, safety, and immunogenicity to ADA. No treatment-emergent issues like increased adverse events, increased immunogenicity, or loss of effectiveness were seen while shifting from ADA to SB5.